Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?
Treatment efficacy, oto- and nephrotoxicity, and aminoglycoside pharmacokinetics were evaluated in a prospective, comparative, randomized clinical study of aminoglycosides given once a day or three times a day for severe infections. Sixty patients were treated with netilmicin or gentamicin 4.5 mg/kg bodyweight/day, either once a day or divided into three doses a day. The patients were allocated randomly to the different groups. The clinical effect was difficult to compare in the different groups, because of the small numbers of patients. Therapeutic failures were seen in seven patients (three after one and four after three doses per day). Two patients, one with Staphylococcus aureus endocarditis and one with streptococcal endocarditis, on netilmicin once daily and conventional high-dose therapy with a penicillin had positive blood cultures after five and seven days of treatment, respectively. Vestibular function and hearing acuity were examined by serial audiograms and electronystagmograms. In spite of extensive diagnostic evaluation, only two cases of ototoxicity were detected. One patient treated with gentamicin three times a day developed vertigo and a severe abnormality of her electronystagmogram. One young patient treated with gentamicin once daily had a slight bilateral reduction of hearing. Nephrotoxicity was mild and did not differ in the four treatment groups. This was the first investigation of a once-daily dosing regimen conducted in seriously ill patients with systemic infections. We could not demonstrate any evidence that aminoglycoside treatment once daily has greater oto- or nephrotoxicity than the traditional three times daily regimen.
Nordström
L
L
Department of Infectious Diseases, University of Lund, General Hospital, Malmö, Sweden.
Ringberg
H
H
Cronberg
S
S
Tjernström
O
O
Walder
M
M
D001299:Audiometry; D001424:Bacterial Infections / Q000188:drug therapy; D003404:Creatinine / Q000097:blood; D004492:Edetic Acid / Q000493:pharmacokinetics; D004584:Electronystagmography / Q000187:drug effects; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000139:chemically induced; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D016032:Randomized Controlled Trials as Topic; D015837:Vestibular Diseases / Q000139:chemically induced; D014724:Vestibular Function Tests
D005839:Gentamicins; D009428:Netilmicin; D004492:Edetic Acid; D003404:Creatinine